Abstract
Cancer being one of the most dreadful disease and inflammation in cancer is one of the emerged Hall marks of cancer. Discovering new drugs with minimal side effects plays vital role in drug development process for the treatment of cancer. As an approach antitumor hybrid of “Benzophenone coupled with diamide analogue “BT009K†or N-(2-{2-[4-(4-bromo-benzoyl)-2-methyl-phenoxy]-acetylamino}-phenyl)-2-[2-methyl-4-(2-methyl-benzoyl)-phenoxy] was screened against different cell lines. Cytotoxic effect was found to be effective against EAC with prolonged effect. The in-vivo antitumor effect was observed in EAC ascites tumour model system with reduced peritoneal neovascularisation. Further histological examination with endothelial marker CD31 confirmed angioregressive effect of BT009K. The results were additionally confirmed in non-tumorigenic model like CAM and rat corneal angiogenesis assay indicating reduced micro vessel density count by BT009K. Further BT009K induces anti-invasive effect in EAC cells in-vitro which could be further developed into therapeutic potential
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
